GPX4 and non-small cell lung carcinoma: However, Tim-AIII-mediated reduction of GPX4 was reversed when cotreated with HSP90 inhibitor tanespimycin (Fig. 5A), indicating that HSP90 was involved in Tim-AIII-triggered reduction of GPX4 in NSCLC cells, and there might be a triple interaction among Tim-AIII, HSP90, and GPX4.